Cargando…

Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma

BACKGROUND: It is well known that renal cell carcinoma (RCC) represents one of the most immune-responsive cancers. Although the lack of defined antigens in RCC has hindered more specific vaccine development, research regarding vaccination therapy has been of special interest for the treatment of RCC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshimura, K, Minami, T, Nozawa, M, Uemura, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619266/ https://www.ncbi.nlm.nih.gov/pubmed/23470466 http://dx.doi.org/10.1038/bjc.2013.90

Ejemplares similares

A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer
por: Suzuki, Nobuaki, et al.
Publicado: (2014)

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
por: Ghatalia, P, et al.
Publicado: (2015)

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
por: Monk, Paul, et al.
Publicado: (2014)

Vascular Endothelial Growth Factor in Tear Samples of Patients with Systemic Sclerosis
por: Rentka, Anikó, et al.
Publicado: (2015)

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
por: Rossi, J-F, et al.
Publicado: (2010)

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
por: Bernhardt, S L, et al.
Publicado: (2006)

Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
por: Nakamura, K, et al.
Publicado: (2005)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma
por: Shen, Jie, et al.
Publicado: (2017)

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
por: Jonasch, E, et al.
Publicado: (2008)

A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications
por: Kelly, S P, et al.
Publicado: (2011)

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis
por: Schoenleber, S J, et al.
Publicado: (2009)

Aqueous Concentrations of Vascular Endothelial Growth Factor in Eyes with High Myopia with and without Choroidal Neovascularization
por: Wakabayashi, Taku, et al.
Publicado: (2013)

Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
por: Inokuchi, M, et al.
Publicado: (2006)

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer
por: Yoshioka, T, et al.
Publicado: (2009)

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
por: Sakiyama, T, et al.
Publicado: (2015)

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study
por: Katsumata, N, et al.
Publicado: (2005)

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
por: Lickliter, J D, et al.
Publicado: (2010)

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part
por: Vermorken, J B, et al.
Publicado: (2011)

Enhanced Vascular Endothelial Growth Factor Gene Expression in Ischaemic Skin of Critical Limb Ischaemia Patients
por: Bleda, Silvia, et al.
Publicado: (2012)

Plasma Vascular Endothelial Growth Factor Dysregulation in Defining Aggressiveness of Head and Neck Squamous Cell Carcinoma
por: Kulapaditharom, Boonchu, et al.
Publicado: (2012)

Vascular Endothelial Growth Factor and Brain-Derived Neurotrophic Factor in Quetiapine Treated First-Episode Psychosis
por: Murphy, Brendan P., et al.
Publicado: (2014)

Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity
por: Chen, Xuting, et al.
Publicado: (2019)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
por: Bauer, S, et al.
Publicado: (2014)

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
por: Dudek, A Z, et al.
Publicado: (2009)

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
por: Takayama, T, et al.
Publicado: (2007)

Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers
por: Fujimoto, J, et al.
Publicado: (2004)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
por: Larkin, J M G, et al.
Publicado: (2010)

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
por: Yamada, Y, et al.
Publicado: (2008)

Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study
por: Sheikh, H Y, et al.
Publicado: (2007)

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
por: Macarulla, T, et al.
Publicado: (2015)

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
por: Hanna, Glenn J., et al.
Publicado: (2023)

Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma
por: Donskov, F, et al.
Publicado: (2005)

Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial
por: Loi, S, et al.
Publicado: (2005)

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
por: Brain, E, et al.
Publicado: (2012)

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011)

Prognostic value of vascular endothelial growth factor receptor 1 and class III β-tubulin in survival for non-metastatic rectal cancer
por: Kong, Xiang-Quan, et al.
Publicado: (2018)

Time-Dependent Changes of Plasma Concentrations of Angiopoietins, Vascular Endothelial Growth Factor, and Soluble Forms of Their Receptors in Nonsmall Cell Lung Cancer Patients Following Surgical Resection
por: Kopczyńska, Ewa, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_02rc465f7c0jqsm7j05kcfgh6p